IRVINE, Calif.—This week Allergan (NYSE: AGN) reported a net loss of $670.5 million for the third quarter, despite an increase in sales for the period. Last year, the company had $239.2 million in net profits in the comparable period.

In Q3, Allergan had total product sales of $1,192 million, up 5.7 percent (up 6.3 percent at constant currency rates). Sales of the company’s eyecare pharmaceuticals rose 6.3 percent, to $568.8 million.

In the nine months ended Sept. 30, Allergan’s net loss was $262.5 million, vs. $399.8 million in net earnings in the same period in 2009. Total product sales in the first nine months of 2010 were $3,529.5 million, vs. $3,241.1 million in the same period last year.

Sales of eyecare pharmaceuticals in 2010’s first nine months were $1,658.6 million, up from $1,534.7 million in last year’s first three quarters.